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Association of visceral adiposity index
with incident nephropathy and retinopathy:
a cohort study in the diabetic population
Zhiyuan Wu1,5, Siqi Yu1, Xiaoping Kang2, Yue Liu1, Zongkai Xu1, Zhiwei Li1, Jinqi Wang1, Xinlei Miao1,
Xiangtong Liu1, Xia Li3, Jingbo Zhang4, Wei Wang5, Lixin Tao1* and Xiuhua Guo1,5*

Abstract
Background: The association between visceral adiposity index (VAI) and diabetic complications has been reported
in cross-sectional studies, while the effect of VAI on complication development remains unclear. This study aims to
evaluate the longitudinal association of VAI and Chinese VAI (CVAI) with the incidence of diabetic nephropathy and
retinopathy using a Chinese cohort.
Methods: A total of 8 948 participants with type 2 diabetes from Beijing Health Management Cohort were enrolled
during 2013–2014, and followed until December 31, 2019. Nephropathy was confirmed by urine albumin/creatinine
ratio and estimated glomerular filtration rate; retinopathy was diagnosed using fundus photograph.
Results: The mean (SD) age was 53.35 (14.66) years, and 6 154 (68.8%) were men. During a median follow-up of
4.82 years, 467 participants developed nephropathy and 90 participants developed retinopathy. One-SD increase in
VAI and CVAI levels were significantly associated with an increased risk of nephropathy, and the adjusted hazard ratios
(HR) were 1.127 (95% CI 1.050–1.210) and 1.165 (95% CI 1.003–1.353), respectively. On contrary, VAI and CVAI level
were not associated with retinopathy after adjusting confounding factors.
Conclusion: VAI and CVAI are independently associated with the development of nephropathy, but not retinopathy
in Chinese adults with diabetes.
Keywords: Visceral adiposity index, Abdominal obesity, Diabetic nephropathy, Diabetic retinopathy
Background
Type 2 diabetes accounts for around 90% of diabetes,
becoming a serious public health issue worldwide. It is
estimated that 366 million people are expected to have
diabetes by 2030, and the vascular complications have
become the leading cause of death in type 2 diabetes
[1, 2]. The vascular complications severely impact the
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patients’ life quality and pose a heavy economic burden
on the health care system [3].
Abdominal obesity is recognized as one of the important risk factors of cardiometabolic diseases [4], diabetes
[5], and diabetic complications [6]. Interestingly, several
studies reported that the distribution of adipose tissue
rather than the total amount is more crucial in the development of vascular complications [7]. X-ray computed
tomography (CT) and magnetic resonance imaging
(MRI) are precise methods to detect abdominal adiposity [8]. However, these methods are expensive, time-consuming and require radiation exposure, and thus they are
not practical for frequent clinical use and epidemiological
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research in general population. Waist circumference
(WC) is a major clinical indicator of increased visceral
fat, which is unable to distinguish between subcutaneous
and visceral fat mass, given the different role of subcutaneous and visceral fat [9]. Thus, some surrogate indexes
of visceral adiposity have been established, including visceral adiposity index (VAI) and Chinese visceral adiposity index (CVAI) [10, 11]. Previous studies [11, 12] have
found that VAI and CVAI could predict the risk of diabetes in adults. Nevertheless, the current evidence about
the association between VAI and diabetic complication
is limited. A recent study [13] reported the cross-sectional associations of VAI and CVAI with diabetic vascular complications. However, the effect of VAI and CVAI
on the development of diabetic complications remains
unclear.
Therefore, this study aims to investigate the longitudinal association of VAI and CVAI with the incidence of
diabetic nephropathy and retinopathy using a population-based cohort.

Methods
Data source and study population

The Beijing health management cohort (BHMC) is an
open cohort study conducted in Beijing Xiaotangshan
Hospital and Beijing Physical Examination Center in Beijing, China. Briefly, the BHMC study is designed to investigate the risk factors and biomarkers for cardiometabolic
diseases, such as metabolic syndrome and type 2 diabetes. The details of the study design have been described
in previous studies [14, 15].
From 2013 to 2014, a total of 47,543 participants aged
20 years or above underwent a comprehensive health
examination, and 10,948 were confirmed to have type 2
diabetes. To minimize the possible influence of reverse
causality, 220 participants with a history of retinopathy
and 478 participants with nephropathy at baseline were
excluded. In addition, we excluded 65 participants with
type 1 diabetes and 1027 participants lacking anthropometric measurement data at baseline. Finally, 8948
participants with complete data were annually followed
under same identical conditions for the development of
nephropathy and retinopathy until December 31, 2019,
and the incident cases in each follow-up year were shown
in Fig. 1. This study was approved by the Ethics Committee of Capital Medical University (Grant Number:
2020SY031). All participants provided written informed
consent.
Data collection

Baseline data on demographic variables and health information, including age, sex, education level, physical activity, smoking status, drinking status, diagnosis history of
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Fig. 1 Flow chart of this current study

diseases and medication use were collected via a standard questionnaire by our trained staff. Educational level
was categorized as illiteracy or primary school, middle
school, high school or above. Smoking status was defined
as ‘current smoker’, ‘former smoker’ and ‘never smoked’.
Drinking status was defined as ‘current drinking’ and ‘no
current drinking’. Physical activity was defined as having
moderate or intense exercise ‘ ≥ 20 min per time and ≥ 4
times per week’. Self-reported health conditions included
the physician-diagnosed history of diabetes, hypertension and dyslipidemia. The uses of antidiabetic, antihypertensive and lipid lowering medication were defined
as a positive response to the following question: ‘Do you
take antidiabetic, antihypertensive or lipid lowering medication regularly following the physician’s prescription?’.
The clinical characteristics and biochemical examination data were obtained from the electronic medical
record system. Anthropometric measurements include
height, weight, and WC. Body mass index (BMI) is calculated as weight (in kilograms)/height2 (in metres
squared). Systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were calculated as the average
of two measurements on the right arm using a sphygmomanometer after resting for at least 10 min. The
overnight fasting venous blood samples were obtained
from all participants, and measured in the central laboratory of Beijing Xiaotangshan Examination Center or
Beijing Physical Examination Center. The data of fasting
blood glucose, glycated haemoglobin (HbA1c), serum
total cholesterol, triglycerides, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, serum creatinine, urinary albumin/creatinine ratio
(ACR) were collected in this current study. The estimated
glomerular filtration rate (eGFR) was calculated using
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the Chronic Kidney Disease Epidemiology Collaboration serum creatinine equation [16]. Hypertension was
defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or use
of any antihypertensive medication or self-reported history of hypertension according to the JNC-7 criteria [17].
Diabetes was defined as fasting glucose ≥ 7.0 mmol/l,
HbA1c ≥ 6.5% or the use of any antidiabetic medication
or self-reported history of diabetes based on the American Diabetes Association [18]. According to the Guidelines on Prevention and Treatment of Dyslipidaemia for
Chinese Adults, dyslipidaemia was defined as triglycerides ≥ 2.3 mmol/l, total cholesterol ≥ 6.2 mmol/l, LDL
cholesterol ≥ 4.1 mmol/l, HDL cholesterol < 1.0 mmol/l,
or any lipid-lowering medication or self-reported history
of dyslipidaemia [19].
Definition of exposure and outcome

Baseline VAI level is calculated using WC, BMI, triglycerides and HDL. CVAI level is calculated using age, WC,
BMI, triglycerides and HDL cholesterol. The sex specific
formula is as follows:
Men:
VA I = W C / ( 3 9 . 6 8 + 1 . 8 8 * B M I ) * ( t r i g l y c e r i
des/1.03)*(1.31/HDL cholesterol).
CVAI = − 267.93 + 0.68*age (years) + 0.03*BMI (kg/
m2) + 4.00*WC (cm) + 22.00*lg [triglycerides (mmol/
l)]−16.32*HDL cholesterol (mmol/l).
Women:
VA I = W C / ( 3 6 . 5 8 + 1 . 8 9 * B M I ) * ( t r i g l y c e r i
des/0.813)*(1.52/HDL cholesterol).
CVAI = − 187.32 + 1.71*age (years) + 4.32*BMI (kg/
m2) + 1.12*WC (cm) + 39.76*lg(triglycerides (mmol/
l))−11.66*HDL cholesterol (mmol/l).
The VAI and CVAI showed significant correlations
with visceral adipose tissue volume as described previously [10, 20].
Diabetic retinopathy was confirmed by ophthalmologists using the 45° four-field stereoscopic digital photography (Carl Zeiss Fundus Camera, Germany) centered
at the central point of macula and optic disc, including
temporal upper, temporal lower, nasal lower, and nasal
upper fields. Non-mydriatic digital images of the retina
for both eyes were taken, and the retinopathy was diagnosed according to the International Clinical Diabetic
Retinopathy Disease Severity Scale [21]. The retinopathy diagnosis could be divided into four severity: mild
non-proliferative; moderate non-proliferative; severe
non-proliferative and proliferative. The presence of any
severity lesion mentioned above was defined as diabetic
retinopathy. Diabetic nephropathy was confirmed as urinary ACR ≥ 30 mg/mmol or eGFR < 60 mL/min/1.73m2
according to the organization Kidney Disease Improving
Global Outcomes (KDIGO) [22–24].
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Statistical analysis

Categorical variables were presented as number (proportions), and continuous variables were presented as mean
(standard deviation, SD) or median (interquartile range,
IQR). Difference between groups were compared using
Chi-square test for categorical variables, and Student’s
t-test or Mann–Whitney U test for continuous variables,
as appropriate.
Baseline VAI and CVAI were centered and standardized before analysis. The follow-up time was calculated
from baseline to the year of nephropathy or retinopathy
diagnosis, loss to follow-up, or the end date (December
31, 2019), whichever came first. The Cox proportional
hazards models were used to investigate the associations
of VAI and CVAI with the risk of incident nephropathy
and retinopathy. To adjust for potential confounding factors, the following models were established: Model 1,
adjusted for age and sex; Model 2, adjusted for age, sex,
education level, smoking status, drinking status, physical
activity, BMI group, hypertension, dyslipidaemia, fasting glucose and the use of antidiabetic medication. The
hazard ratio (HR) and 95% confidence interval (CI) were
provided. The restricted cubic spline function was used
to analyze the dose–response relationship of VAI and
CVAI with outcome. The discriminatory power of VAI
and CVAI was shown using time-dependent receiver
operating characteristics (ROC) curve and C-statistic. To
identify the modification effect of potential variables, the
interactive terms were tested in the model. In addition,
we calculated the associations of the tertiles of VAI and
CVAI with the diabetic complications, and the individuals were divided into lower, middle and upper groups of
VAI and CVAI.
We performed multiple sensitivity analyses. First, participants experiencing a event of nephropathy or retinopathy within one year were excluded. Second, we repeated
the analysis in people without the use of antidiabetic
medication. Third, HbA1c level was further adjusted to
explore the stability of our findings.
All the analyses mentioned above were conducted
using R software, version 4.1.0 (R Foundation). The difference was considered statistically significant at two-side
significance level of P < 0.05.

Results
The final analysis included 8 948 individuals with type 2
diabetes, and 6 154 (68.8%) were men. The mean (SD) age
of this population was 53.35 (14.66) years. The median
[IQR] of baseline VAI and CVAI were 1.46 [0.90,2.37]
and 112.60 [77.19,143.17]. During a median follow-up of
4.82 years, 467 participants developed nephropathy and
90 participants developed retinopathy. Table 1 shows the
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Table 1 Baseline characteristics of the study population
Overall (n = 8948)

DN- (n = 8481)

DN + (n = 467)

P value DR- (n = 8858)
< 0.001 53.33 (14.70)

DR + (n = 90)

P value

Age, years

53.35 (14.66)

52.42 (14.19)

70.27 (12.70)

Men, n (%)

6154 (68.8)

5825 (68.7)

329 (70.4)

0.453 6074 (68.6)

80 (88.9)

55.88 (10.25)

< 0.001

0.101

900 (10.6)

55 (11.8)

0.320 939 (10.6)

16 (17.8)

0.003

Education, n (%)
Primary school or 955 (10.7)
below
Middle school

6054 (67.7)

5731 (67.6)

323 (69.2)

5988 (67.6)

66 (73.3)

High school or
above

1939 (21.7)

1850 (21.8)

89 (19.1)

1931 (21.8)

8 (8.9)

Physical activity
(n, %)

3755 (42.0)

3546 (41.8)

209 (44.8)

0.228 3721 (42.0)

34 (37.8)

0.483

Current smoking
(n, %)

2709 (30.3)

2592 (30.6)

117 (25.1)

0.013 2668 (30.1)

41 (45.6)

0.002

Current drinking
(n, %)

5067 (56.6)

4832 (57.0)

235 (50.3)

0.005 5013 (56.6)

54 (60.0)

0.588

BMI, kg/m2

25.48 (3.36)

25.46 (3.37)

25.86 (3.27)

0.012 25.47 (3.37)

26.23 (3.15)

0.033

WC, cm

87.32 (10.18)

87.17 (10.18)

90.02 (9.75)

< 0.001 87.27 (10.18)

91.70 (8.33)

< 0.001

Hypertension (n, %)

3607 (40.3)

3262 (38.5)

345 (73.9)

< 0.001 3559 (40.2)

48 (53.3)

0.015

Dyslipidaemia (n, %) 3328 (37.2)

3138 (37.0)

190 (40.7)

0.120 3282 (37.1)

46 (51.1)

0.008
< 0.001

Antidiabetic (n, %)

1198 (13.4)

1075 (12.7)

123 (26.3)

< 0.001 1128 (12.7)

70 (77.8)

Antihypertensive
(n, %)

732 (8.2)

659 (7.8)

73 (15.6)

< 0.001 728 (8.2)

4 (4.4)

0.268

Lipid lowering (n, %) 492 (5.5)

438 (5.2)

54 (11.6)

< 0.001 488 (5.5)

4 (4.4)

Fasting glucose,
mmol/L

5.30 [4.93,5.93]

5.50 [5.04,6.32]

< 0.001 5.30 [4.93,5.91]

8.32 [7.21,12.07]

< 0.001

5.31 [4.94,5.94]

0.835

HbA1c, %

5.57 [5.31,5.96]

5.56 [5.30,5.94]

5.80 [5.54,6.24]

< 0.001 5.57 [5.31,5.95]

7.53 [6.54,9.09]

< 0.001

Triglycerides,
mmol/L

1.27 [0.89,1.87]

1.27 [0.89,1.88]

1.21 [0.91,1.77]

0.479 1.27 [0.89,1.87]

1.38 [0.96,2.19]

0.143
< 0.001

HDL-C, mmol/L

1.26 [1.06,1.53]

1.26 [1.06,1.53]

1.25 [1.05,1.56]

0.945 1.26 [1.06,1.53]

1.17 [0.97,1.34]

VAI

1.46 [0.90,2.37]

1.45 [0.90,2.36]

1.76 [1.03,2.80]

0.043 1.46 [0.89,2.37]

1.45 [0.95,2.32]

0.984

CVAI

112.60
[77.19,143.17]

111.07
[75.68,141.98]

136.62
[107.49,160.81]

125.61
[104.48,154.95]

< 0.001

< 0.001 112.44
[76.88,143.07]

Data are the mean (SD), median [IQR] or number (%)
To convert fasting glucose to mg/dL, multiply by 18; triglycerides to mg/dL multiply by 28.25
DR diabetic retinopathy, DN diabetic nephropathy, BMI body mass index, HbA1c glycated haemoglobin, HDL-C high-density lipoprotein cholesterol, VAI visceral
adiposity index, CVAI Chinese visceral adiposity index

baseline characteristics of participants according to the
complication development or not. The CVAI levels were
significantly higher in the nephropathy and retinopathy
groups, while the VAI level was only significantly higher
in the nephropathy group. The baseline characteristics of
participants according to the tertiles of baseline VAI and
CVAI index are shown in Additional file 1: Table S1 and
Table S2.
In the fully adjusted model, one-SD increase in VAI
and CVAI levels were significantly associated with an
increased risk of nephropathy, and the HR values were
1.127 (95% CI 1.050–1.210) and 1.165 (95% CI 1.003–
1.353), respectively. On contrary, VAI and CVAI levels
were not significantly associated with retinopathy after
adjusting confounding factors, and the HR values were

1.071 (95% CI 0.950–1.207) and 0.878 (95% CI 0.615–
1.252), as shown in Table 2. The full regression results are
shown in Additional file 1: Table S3, and fasting glucose
level and hypertension had a significant impact on the
microvascular complications. The dose–response relationship of VAI and CVAI with the risk of nephropathy
development is presented in Fig. 2. The C-statistic values of VAI and CVAI for predicting the development of
nephropathy were 0.632 [95% CI 0.585–0.678] and 0.617
[95% CI 0.584–0.651], as shown in Fig. 3. The C-statistic
values for predicting retinopathy is presented in Additional file 2: Fig. S1.
In addition, we observed no significant interaction
effect of age, sex, obesity, smoking with VAI and CVAI for
incident nephropathy (Additional file 1: Table S4). Table 3
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Table 2 Association of visceral adiposity indexes with the development of diabetic nephropathy and retinopathy
Hazard ratio (95% CI)
Model 1

P value

Model 2

P value

Nephropathy
VAI per-SD increase

1.154 (1.095–1.217)

< 0.001

1.127 (1.050–1.210)

0.001

CVAI per-SD increase

1.296 (1.159–1.450)

< 0.001

1.165 (1.003–1.353)

0.045

Retinopathy
VAI per-SD increase

0.739 (0.549–0.995)

0.047

1.071 (0.950–1.207)

0.264

CVAI per-SD increase

1.330 (1.038–1.704)

0.024

0.878 (0.615–1.252)

0.471

Model 1: adjusted for age and sex
Model 2: age, sex, BMI group, education level, smoking status, drinking status, physical activity, hypertension, dyslipidaemia, fasting glucose and use of antidiabetic
medication
VAI visceral adiposity index, CVAI Chinese visceral adiposity index

Fig. 3 Time-dependent ROC curves of VAI and CVAI for predicting
diabetic nephropathy development

Fig. 2 Dose–response relationship of baseline VAI and CVAI with
incident nephropathy after adjusting for age and sex

summarizes the association of the tertiles of VAI and
CVAI with the incidence of nephropathy and retinopathy. Individuals in the highest tertile of VAI were significantly associated with an increased risk of nephropathy,
compared with those in the lowest tertile (adjusted HR:
1.338, 95% CI 1.033–1.735, P value: 0.028). Significant
association was not observed between CVAI tertiles and
incident nephropathy. Tertiles of VAI and CVAI were not
associated with the development of retinopathy.
We repeated the analysis after excluding participants
who developed nephropathy within one year. Only VAI
was significantly associated with incident nephropathy (HR: 1.115, 95% CI 1.010–1.230). After excluding

participants using antidiabetic medication, we found that
VAI, not CVAI was significantly associated with incident nephropathy (HR: 1.142, 95% CI 1.007–1.295). The
results remained almost consistent when HbA1c level
was further adjusted, and VAI was independently associated with nephropathy development (HR: 1.130, 95% CI
1.053–1.211), as shown in Fig. 4.

Discussion
This study evaluated the longitudinal association of visceral adiposity index with the development of nephropathy and retinopathy in a diabetic population. In the
current analysis, we found that One-SD increase of VAI
and CVAI levels were significantly associated with an
increased risk of nephropathy, but not retinopathy in
Chinese adults with diabetes after adjusting confounding
factors. In the multiple sensitivity analyses, we found that
VAI was more independently associated with incident
nephropathy than CVAI.
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Table 3 Association of the tertiles of visceral adiposity indexes with the development of diabetic nephropathy and retinopathy
Hazard ratio (95% CI)
Model 1

P value

Model 2

P value

Nephropathy
VAI (ref: lower)

–

Middle

1.222 (0.976–1.531)

0.080

–
1.098 (0.873–1.382)

0.425

Upper

1.571 (1.251–1.973)

< 0.001

1.338 (1.033–1.735)

0.028

CVAI (ref: lower)

–

Middle

1.136 (0.851–1.516)

0.387

0.989 (0.737–1.325)

0.938

Upper

1.690 (1.293–2.208)

< 0.001

1.317 (0.975–1.780)

0.073

–

Retinopathy
VAI (ref: lower)

–

Middle

1.025 (0.587–1.790)

0.930

–
0.765 (0.431–1.361)

0.363

Upper

1.536 (0.915–2.578)

0.104

0.696 (0.354–1.367)

0.292

CVAI (ref: lower)

–

Middle

2.198 (1.119–4.317)

0.022

1.369 (0.688–2.722)

0.371

Upper

2.335 (1.188–4.589)

0.014

1.134 (0.518–2.484)

0.754

–

Model 1: adjusted for age and sex
Model 2: age, sex, BMI group, education level, smoking status, drinking status, physical activity, hypertension, dyslipidaemia, fasting glucose and use of antidiabetic
medication;
VAI visceral adiposity index, CVAI Chinese visceral adiposity index

Fig. 4 Association of VAI and CVAI with incident nephropathy in sensitivity analyses

Previous studies found that excess visceral fat, but
not general adiposity, is strongly correlated with incident prediabetes and type 2 diabetes in obese adults
[25, 26]. Some studies indicated that, as a simple indicator of visceral adipose function, VAI and CVAI could
increase the risk of prediabetes and type 2 diabetes. Xia
et al. [11, 27] reported that CVAI is a stronger predictor of prediabetes and diabetes than traditional indexes
such as BMI and WC. Similarly, TZou et al. [28] found
that CVAI and VAI may serve as potential indicators of
diabetes. In addition, some studies reported that VAI

is correlated with the risk of macrovascular complications in diabetic population [29, 30]. However, data on
the associations of VAI and CVAI with diabetic microvascular complications are relatively limited. Several
cross-sectional studies reported that VAI is an independent risk factor for excess urinary albumin excretion and diabetic nephropathy [31–33], and CVAI is
closely associated with the prevalence of cardiovascular diseases and diabetic nephropathy [13]. In this
current study, we found that VAI and CVAI levels at
baseline are positively associated with the development
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of nephropathy in diabetic population using a cohort
design.
Although the underlying mechanisms of VAI with
diabetic nephropathy have not been fully illustrated,
there are several possible explanations accounting for
the observed associations. First, VAI is a representative marker to assess visceral adiposity which is strongly
related with insulin resistance [34], and insulin resistance may lead to hypo-inflammation [35], endothelium
dysfunction [36], and oxidative stress [37], contributing to the development of microangiopathy. Podocytes
are insulin sensitive renal cells, and thus the insulin
resistance is more likely to cause kidney damage [38].
Second, VAI is a valuable indicator of visceral adipose
function [10]. The release of free fatty acids from central and visceral adipose tissue can increase the secretion of pro-inflammatory factors [39], such as TNF-α and
interleukin-6, which could cause glomerular endothelial
dysfunction and increase urine albumin. Third, obesity
may also directly affect renal pathophysiology through
the altered renal hemodynamics, as well as the production of adipokines and growth factors [40]. Adipokines
are involved in microvascular injury and kidney damage
by mediating endothelial dysfunction, inducing oxidative
stress, inflammation, activation of the renin–angiotensin–aldosterone system [41] and endoplasmic reticulum
stress [42]. All these mechanisms could partly explain the
positive association between VAI and the development of
nephropathy.
Wan et al. [13] found that VAI and CVAI were associated with a higher prevalence of diabetic nephropathy.
While multiple sensitivity analyses in our study did not
find a stable association between baseline CVAI and the
incidence of diabetic nephropathy. The distinct formulas
of calculating VAI and CVAI may account for this difference. In our study, the individuals with diabetic nephropathy were much older. Previous studies have shown that
visceral adipose tissue is not associated with incident
atherosclerotic cardiovascular events in older men [43].
Therefore, visceral adipose tissue may not have a strong
adverse effect on health in relatively older people. CVAI
is calculated based on age, BMI, WC, triglycerides, and
HDL-C, while VAI is calculated independent of age and
thus may be more useful for predicting the development
of diabetic nephropathy. More studies in Chinese population are needed to confirm the association of VAI and
CVAI with incident diabetic complications.
In this study, we did not find a positive association of
VAI and CVAI with incident diabetic retinopathy, which
is different from some other studies. Moh et al. [44]
reported that visceral adiposity is associated with diabetic
retinopathy in an Asian cohort with longstanding type 2
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diabetes for 10 years. Of note, the cumulative incidence
of diabetic retinopathy was only 1.0% in our study, while
the annual incidence of diabetic retinopathy ranged from
2.2% to 12.7% from other Asia, North America, Caribbean, and sub-Saharan Africa studies [45], which indicates the participants in our cohort were at a relatively
early stage of diabetes. In addition, the participants were
annually physically examined and thus advised by our
trained staff about the glucose control. The glucose and
HbA1c levels were not severely high in this cohort, which
could partially explain the low incidence of diabetic retinopathy. In addition, Moh et al. [44] found that the association between visceral adiposity and diabetic retinopathy
became insignificant after controlling for ACR and eGFR,
and thus the relationship may be attributable to vascular
injury reflected by coexisting renal burden. Therefore, the
visceral adiposity could be more strongly associated with
renal function and nephropathy, which is also indicated
in our study.
Our study is based on a population cohort of people
with type 2 diabetes, which could explain the longitudinal associations of VAI and CVAI with the development
of diabetic complications. In addition, the data were
obtained from the central medical system or using the
standardized questionnaire, which allow us to adjust
for the potential confounding factors. However, several limitations in our study should be acknowledged.
First, the visceral adiposity was not directly measured
by MRI method, and we failed to examine the consistence between actual visceral fat mass and VAI in Chinese
population. Second, the exact duration of diabetes in this
cohort was unavailable, and the duration is an important
risk factor of diabetic complication, which could bias
the relationship between VAI and diabetic nephropathy.
Third, information about the neurological complication
is unavailable in this current cohort. We failed to assess
the longitudinal association between VAI and the neuropathy development in diabetic population.

Conclusions
Our findings suggest that elevated levels of VAI and CVAI
at baseline are significantly associated with increased risk
of incident nephropathy, but not retinopathy in diabetic
population.
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